What factors would lead you to extend the duration of antithyroid drug therapy in a patient with Graves' disease who is clinically euthyroid at 12 months but has risk factors for recurrence?
What factors help you decide the duration of antithyroid drug therapy in a patient with Graves' disease who is clinically euthyroid?
Join Mednetto vote and see how they answered.
One should never discontinue methimazole after an arbitrary period of time without checking anti-TSH receptor antibody levels. If they are positive or even “normal” but not undetectable, the patient will inevitably have a recurrence of their hyperthyroidism relatively quickly (Laurberg et al., PMID ...
Join for free or sign in to see the full answer
Agree with Dr. @Dr. First Last. The patients rely on our guidance for ATD, versus RAI, and rarely surgery. It is expensive for some patients to continue to have visits and tft's several times a year on ATD, compared to patients who may have post-ablative hypothyroid on stable thyroxine treatment who...
Join for free or sign in to see the full answer
Join for free or sign in to see the full answer